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ABSTRACT Antisense 2'-O-methylribooligonucleotides
were targted ainst sp sequence elements in mutated
human f-globin pre-mRNAs to restore correct splicing of these
RNAs in vitro. The foflowing mutations of the P-globin gene, A
G at nt 110 of the first intron (Pll(D), T -* G at nt 705 and C
- T at nt 654 of the second intron (IVS275 and IVS204,
respectively), which led toaberrant spcing of the corresponding
pre-mRNAs, were previously identified as the underlying causes
of hemIa. Aberrant splcing of pllo pre-mRNA was
efficiently reversed by an olgonucleotide taeted aginst the
branch point sequence in the first intron of the pre-mRNA but
not by an oligonuceotide targeted against the aberrant 3' splice
site. In both IVS27u and IVS26" pre-mRNAs, correct splicing
was restored by oligonucleotides targeted apinst the aberrant 5'
splice sites created by the mutations in the second intron or
against a cryptic 3' splice site located upsteam and activated in
the mutated backgrud. These experiments represent an ap-
proach in which antisense ogo tides are used to restore
the f of a defective gene and not, as usual, to down-
regulate the expression of an underable gene.
The potential of oligonucleotides as modulators of gene ex-
pression and as chemotherapeutic agents is currently under
intense investigation. Rapidly accumulating literature has
been surveyed in a number of recent reviews (1-4). The
activity of antisense oligonucleotides generally relies on their
hybridization with targeted RNA, leading either to its degra-
dation by cellularRNaseH orto a block in its translation (1-4).
In another approach, so-called antigene oligonucleotides are
directed against specific regions in DNA, where they form
triplex structures and inhibit transcription by RNA polymer-
ase 11(5, 6). Both antisense and antigene oligonucleotides lead
to down-regulation oftargeted genes and are applied to reduce
the intracellular level of undesirable gene products coded by
viruses (7, 8), other pathogens (9), or oncogenes (2). This is
difficult to accomplish, especially ifthe targeted gene codes for
a protein that is stable and has a low turnover rate.
In the approach reported here, antisense oligonucleotides
are designed to generate a correctgene product that had been
rendered defective by mutations that changed the splicing
pattern of the corresponding pre-mRNA. We have used oli-
gonucleotides complementary to specific sequence elements
in pre-mRNAs coded by mutated (-globin alleles identified in
various cases of (-thalassemia. In this model system of
potential clinical significance (10), the oligonucleotides sup-
pressed abenrant splicing pattern of ,B-globin pre-mRNA re-
sulting from gene mutations and restored correct splicing.
MATERIALS AND METHODS
All pre-mRNAs were transcribed by SP6 RNA polymerase
(11) from appropriate fragments of the human (-globin gene
subcloned into the SP64 vector. HBA6 (12) contains the
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whole human f-globin gene, consisting of three exons and
two introns. The (3110 construct, carrying an A -* G mutation
at position 110 of the first intron, was obtained by subcloning
a fragment from the original thalassemic clone (ref. 13; P. J.
Furdon and R.K., unpublished data) into HBA6 plasmid. To
construct clones containing thalassemic mutations in the
second intron, a fragment ofhuman (3-globin gene containing
virtually the entire second exon, the entire second intron, and
a major portion ofthe third exon was subcloned into the SP64
vector. The resulting IVS2 clone was subsequently subjected
to site-specific mutagenesis (14). A mutation of T -- G at nt
705 of the intron was introduced to construct the IVS2705
clone, and a C -- T mutation was introduced at nucleotide 654
to construct the IVS2654 clone. Further details of the con-
struction are available upon request. Transcription was car-
ried out on a plasmid linearized at the BamHI site for the (110
clone or at the Pvu II site for the IVS2705 and IVS2654 clones.
The oligonucleotides were synthesized at the Lineberger
Comprehensive Cancer Center using reagents from Glen
Research (Sterling, VA) and purified using SurePure kit
(United States Biochemical). The concentration of the oli-
gonucleotides was measured spectrophotometrically at 260
nm. The sequence ofthe oligonucleotides is shown in Fig. 1B.
Nuclear extract from HeLa cells was prepared as described
(12) except that the pellet ofthe nuclei was initially suspended
in 0.5 vol of buffer C [20 mM Hepes, pH 7.9/25% (wt/vol)
glycerol, 1.5 mM MgCl2/0.2 mM EDTA/0.5 mM dithiothrei-
tol/20 mM KCl] and subsequently supplemented with an-
other 0.5 vol of buffer C containing 1.2 M KCI. Splicing of
32P-labeled pre-mRNAs (P405 cpm per reaction, 25 fmol) was
carried out in the nuclear extract for 2 hr at 30°C in a reaction
volume of 25 pl (12, 15). Antisense oligonucleotides were
added together with the other components of the splicing
reaction. Reaction products were analyzed on an 8% poly-
acrylamide sequencing gel and visualized by autoradiogra-
phy.
All autoradiograms were captured by a Dage-MTI CCD-72
video camera (Michigan City, IN), and the images were
processed using National Institutes of Health IMAGE 1.43 and
MAcDRAw PRO 1.0 software. The final figures were printed
out on Sony dye sublimation printer.
RESULTS AND DISCUSSION
Restoration of Correct Splicing in Intron 1 of Human
3-Globin Pre-mRNA. In 81"0-thalassemia, a form of the
disease predominant in thalassemic individuals ofGreek and
Cypriot origin (10, 16), an A-+ G mutation at nt 110 ofthe first
intron of the human 3-globin gene creates an additional,
aberrant 3' splice site (13). In spite of the presence of the
normal 3' splice site, the aberrant site is preferentially used
by the splicing machinery, resulting in an incorrectly spliced
mRNA that contains 19 nt of the intron sequence (Fig. 1). In
cells transfected with the (3110-globin allele, correctly spliced
mRNA constitutes only about 10%o ofthe spliced product (17,
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18), in agreement with the markedly reduced levels ofnormal
hemoglobin observed in patients with this form of thalas-
semia (10). It was found that in (3"'O pre-mRNA the aberrant
3' splice site utilizes the normal branch point at nt 93 of the
intron, competing with the correct 3' splice site and thereby
reducing correct splicing (19). Significantly for this work,
mutations inactivating this element activate a cryptic branch
point at nt 107 and result in splicing at the correct 3' splice site
(20). Aberrant splicing cannot proceed in the mutated back-
ground due to the proximity ofthe 3' splice site at position 110
to the cryptic branch point. We therefore reasoned that
antisense oligonucleotides complementary to the normal
branch point sequence will, like mutations, block its function
in splicing and force the splicing machinery to select the
cryptic branch point, generating correctly spliced mRNA.
To test this idea, a 14-mer 2'-O-methyloligonucleotide
(oligonucleotide 1, Fig. 1) was targeted against the branch
point sequence in intron 1 of 3-globinpre-mRNA. The branch
point nucleotide is located at position 94 ofthe intron, and the
oligonucleotide spans positions 82-95. The 2'-O-methyloli-
gonucleotides were selected for this and subsequent exper-
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stable hybrids with RNA that are not degraded by RNase H
(21-23). Degradation by RNase H, seen when antisense
oligodeoxynucleotides or their phosphorothioate derivatives
are used (1-4), would destroy the substrate pre-mRNA and
prevent splicing. The oligonucleotides were added to an in
vitro splicing reaction containing 32P-labeled pre-mRNA
(-25 fmol, 0.5 nM) and a nuclear extract from HeLa cells.
Analysis of splicing of 8110 pre-mRNA by polyacrylamide gel
electrophoresis shows that, consistent with a previous report
(19), in the control reaction without the oligonucleotide (Fig.
2, lane 2) the ratio of the incorrectly to correctly spliced
products is t9:1. Addition of oligonucleotide 1 at 0.05-5 pM
concentrations causes dose-dependent inhibition of aberrant
splicing and induction of correct splicing of the substrate
(Fig. 2, lanes 3-6). At a concentration of 5 ,uM, oligonucle-
otide 1 reverses the ratio of the incorrectly to correctly
spliced products to 1:5. Apparently, oligonucleotide 1 hy-
bridizes to the normal branch point and prevents binding of
the splicing factors to this sequence element, forcing them to
select the cryptic branch point downstream. The effect of
oligonucleotide 1 must be sequence specific, since it is
unlikely that its hybridization with any other site on the
pre-mRNA would promote the observed results (see below).
Sequence specificity of oligonucleotide 1 is further demon-
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FiG. 1. (A) Structure of pre-mRNAs. Boxes indicate exons;
heavy lines indicate introns. Positions of the mutations (110 or 654
and 705) relative to nt 1 of intron 1 and intron 2, respectively, are
shown above the HBA6 clone. Numbers below indicate the length,
in nucleotides, of exons and introns. Antisense oligonucleotides are
indicated by the numbered short bars below p110, IVS204, and
IVS2705 constructs, and splicing pathways are indicated by the
dashed lines. (B) Sequence of antisense 2'-O-methyloligoribonucleo-
tides. Oligonucleotide 1, complementary to nt 82-95 of intron 1, is
targeted against the normal branch point (BP); oligonucleotide 2 (nt
103-116) is targeted against the aberrant 3' splice site created by Pilo
mutation in intron 1 of the ,-globin gene. Oligonucleotide 3, com-
plementary to nt 573-589 of intron 2, is targeted against the cryptic
3' (cr. 3') splice site at nt 579 of the second intron; oligonucleotide
4 (nt 697-713) is targeted against the aberrant 5' splice site created by
the mutation at nt 705 in the second intron of IVS2705 pre-mRNA;
oligonucleotide 5 (nt 643-660) is targeted against the aberrant 5'















FIG. 2. Reversal of aberrant splicing by oligonucleotide 1 di-
rected against the normal branch point in intron 1 of ,B-globin
pre-mRNA. In this and subsequent experiments, in vitro splicing was
carried out as described in Materials and Methods. Reaction prod-
ucts were analyzed on an 8% polyacrylamide sequencing gel and
visualized by autoradiography. The structure of the products and
intermediates is depicted on the right; their size in nucleotides is
shown on the left. An asterisk denotes aberrant mobility of lariat-
containing intermediates. The same designations are used in subse-
quent figures. Lane 1, splicing of control HBA6 pre-mRNA. Lane 2,
splicing of (8110 pre-mRNA. Lanes 3-6, splicing of (311O pre-mRNA in
the presence of increasing concentrations (pM; indicated at the top
ofthe figure) ofoligonucleotide 1. Lane 7, splicing of 110pre-mRNA
in the presence of oligonucleotide 3, targeted to a sequence in intron
2 of (-globin pre-mRNA.
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strated by the fact that at S ,uM an oligonucleotide targeted
against the cryptic 3' splice site in the second intron of the
(3-globin gene (oligonucleotide 3, Fig. 1; see also below) does
not affect the original ratio of the spliced products (Fig. 2,
lane 7). At higher concentrations (10-20 .M), oligonucleotide
1 inhibits splicing in an unspecific manner and generates
greater amounts of an =240-nt RNA species, which is de-
tectable in small quantities at a S jAM concentration of
oligonucleotide 1 (Fig. 2, lane 6). This product accumulates
only in the presence of ATP and other components of the
splicing mixture, and its length is consistent with cleavage of
the RNA at the site of hybridization with the oligonucleotide.
These results suggest the presence of an ATP-dependent
nuclease that either recognizes RNA-2'-O-methyloligonucle-
otide duplexes and cleaves the RNA in an endonucleolytic
manner or degrades RNA exonucleolytically and is blocked
at the site of duplex formation.
The aberrant 3' splice site generated by the (3O mutation
at position 111 appears to be an obvious target for reversal of
aberrant splicing by an antisense oligonucleotide. Blocking
this sequence element should be the simplest way of forcing
the splicing machinery to use the original 3' splice site at the
end of the intron. However, a 14-mer (oligonucleotide 2, Fig.
1) directed against the aberrant splice site, spanning nt
103-116 in the intron, was not effective; at increasing con-
centrations ofoligonucleotide 2, accumulation ofboth spliced
products was inhibited; the correct one was inhibited some-
what more efficiently (Fig. 3, lanes 2-5). Interestingly, the
first step of the splicing reaction, cleavage at the 5' splice site
and formation of the lariat-exon intermediate, seems to be
less affected by oligonucleotide 2 than the formation of the
final spliced product. This is shown by the presence of the
intermediates generated during this step even at 5 and 10 ,uM
concentrations of oligonucleotide 2 (Fig. 3, lanes 5 and 6). At
higher concentrations of the oligonucleotide, cleavage at the
5' splice site was also inhibited (data not shown).
The lack of success with oligonucleotide 2 may result from
the proximity of the aberrant and correct 3' splice sites and,
in consequence, the concomitant interference of this oligo-
nucleotide with both splicing pathways. Note that in p110
pre-mRNA the sequence elements important for splicing
(i.e., the two 3' splice sites, two branch point elements, and
the polypyrimidine tract) are located within the stretch of 37
nt. Conceivably, hybridization of oligonucleotide 2 in the
middle ofthis region interferes with binding of a large number
of splicing factors assembling there and prevents any splicing
by steric hindrance. Consistent with this idea, additional
experiments showed that any oligonucleotide targeted down-
stream from the normal branch point and upstream from the
correct 3' splice site inhibited splicing without restoring the
correct pathway (results not shown). Note also that oligo-
nucleotide 2, as well as some other oligonucleotides targeted
to this region, block a significant portion of the polypyrimi-
dine tract, which is essential for splicing.
Restoration of Correct Splicing In Intron 2 of the Human
P-GIobin Gene. Whether an aberrant 3' splice site can nev-
ertheless be used as a target for reversal of incorrect splicing
was further tested on pre-mRNA carrying a T -- G mutation
at position 705 of the second intron of human 3-globin gene.
This rare mutation (IVS2705), found in Mediterranean
thalassemia patients (10, 16), creates an additional, aberrant
5' splice site and activates a cryptic 3' splice site at position
579 of the intron (24). The incorrect splicing pathway results
in the removal of nt 1-578 and 706-850 as separate introns
and incorporation of the remaining portion of the intron into
the spliced product (Fig. 1). In IVS2705 pre-mRNA the
distances between each of the sequence elements involved in
splicing exceed 100 nt, and no steric hindrance effects caused
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FIG. 3. Effects of oligonucleotide 2, directed against the aberrant
3' splice site in intron 1 of 8lu0 pre-mRNA. Lane 1, splicing of BluO
pre-mRNA. Lanes 2-6, splicing of l"O pre-mRNA in the presence
of increasing concentrations (pM; indicated at the top of the figure)
of oligonucleotide 2.
The control transcript (IVS2) containing the second intron
of normal ,B-globin pre-mRNA is spliced efficiently, gener-
ating the expected intermediates (the 5' exon and the large
lariats) and a 451-nt correctly spliced product (Fig. 4, lane 1).
Note that the splicing of long transcripts and the removal of
long introns have been difficult to achieve in vitro. The high
efficiency of the reaction seen here and in the following
experiment is probably due to the improvement in the prep-
aration of the nuclear splicing extracts. Splicing of IVS2705
pre-mRNA is also efficient and yields an additional spliced
product 577 nt long as well as the expected 722- and 348-mer
intermediates, resulting from the aberrant splicing pathway
caused by the mutation (Fig. 4, lane 2). The 1:2 ratio of
correctly to incorrectly spliced RNAs is similar to that
observed in vivo (24). Oligonucleotide 3, spanning positions
573-589 of intron 2 (Fig. 1) and complementary to the
activated cryptic 3' splice site at nt 579, is very effective; it
induces a dose-dependent reversal of splicing to the correct
splicing pathway (Fig. 4, lanes 3-5). There is a significant
accumulation of the correctly spliced product at a 0.12 IAM
concentration of the oligonucleotide (Fig. 4, lane 3); at 0.5
and 2 FM the restoration of correct splicing is virtually
complete. Correct splicing is also completely restored at
similar concentrations of oligonucleotide 4 (Fig. 1), spanning
positions 697-713 of the intron and targeted against the
aberrant 5' splice site created by the mutation at nt 705 (Fig.
4, lanes 6-8). At higher concentrations of this oligonucleotide
(5 and 10 ,uM), correct splicing remains very efficient;
however, at 20 uM, unspecific inhibition of splicing occurred.
A control experiment, in which splicing ofIVS705 pre-mRNA
is carried out in the presence of 5 ,uM oligonucleotide 1,
shows no effect on the ratio of correctly to incorrectly spliced
Biochemistry: Dominski and Kole
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FIG. 4. Reversal of aberrant splicing of IVS2705 pre-mRNA by
oligonucleotide 3, directed against the aberrant 3' splice site, and
oligonucleotide 4, directed against the aberrant 5' splice site in intron
2 of the IVS2705 pre-mRNA. Lanes 1 and 2, splicing of control
transcripts (indicated at the top of the figure). Lanes 3-5 and 6-8,
splicing of IVS2705 pre-mRNA in the presence of oligonucleotide 3
and oligonucleotide 4, respectively. The concentrations of the oli-
gonucleotides in the reaction (pM) are indicated at the top of the
figure. The band at the top of the gel contains unresolved interme-
diates and products containing large lariats. The numbers 1079 and
850 represent the number of nucleotides in the lariat and lariat-exon
generated by the correct splicing pathway. The RNA band at 722 nt
contains an intermediate of the aberrant splicing pathway with the
upstream, aberrant intron already removed. After cleavage at the
aberrant 5' splice site, its size is reduced to 348 nt.
products (data not shown). This is further evidence of the
high specificity of oligonucleotides used in these studies.
The IVS2654 mutation (25), frequently identified in
thalassemic individuals ofChinese origin (16), affects splicing
via a mechanism analogous to that operating in the IVS705
mutant-i.e., by creating an additional 5' splice site at nt 653
and activating the common cryptic 3' splice site at nt 579 of
intron 2. Splicing patterns of both mutated pre-mRNAs are
presented side by side in Fig. 5, lanes 1 and 2. Different
lengths of incorrectly spliced products and of some of the
intermediates reflect the different positions of aberrant 5'
splice sites in IVS2654 and IVS705 mutants. The efficiency of
aberrant splicing ofIVS2654 pre-mRNA is higher than that for
IVS2705 pre-mRNA, and only small amounts of correctly
spliced product, relative to the aberrant one, are detectable
during splicing in vitro (Fig. 5, lane 2). In spite of the high
efficiency of aberrant splicing, oligonucleotide 3, targeted
against the cryptic 3' splice site, as well as oligonucleotide 5,
spanning nt 643-660 and targeted against the aberrant 5'
splice site (Fig. 1), restored correct splicing efficiently at
concentrations similar to those used in the preceding exper-
iment (Fig. 4). At a 2 ,uM concentration of either oligonucle-
otide, the correctly spliced product accumulates, and the
aberrant product is virtually undetectable (Fig. 5, lanes 7 and
11, respectively).
The results presented in Figs. 4 and 5 demonstrate that
aberrant 3' and 5' splice sites provide suitable targets for
specific reversal of incorrect splicing. Similar effects of
oligonucleotides 3, 4, and 5 suggest that there are no major
differences in their accessibilities to the target splice sites. All
-m
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FIG. 5. Reversal of aberrant splicing of IVS2654 pre-mRNA by
oligonucleotide 3, directed against the aberrant 3' splice site, and
oligonucleotide 5, directed against the aberrant 5' splice site in intron
2 of the IVS2654 pre-mRNA. Lanes 1 and 2, splicing of control
transcripts (indicated at the top of the figure). Lanes 3-7 and 8-11,
splicing of IVS2654 pre-mRNA in the presence of oligonucleotide 3
and oligonucleotide 5, respectively. The concentrations of the oli-
gonucleotides in the reaction (pM) are indicated at the top of the
figure. Other symbols are as described in the legends to the previous
figures.
three oligonucleotides are several times more effective than
oligonucleotide 1 used in the experiments shown in Fig. 2.
The higher efficacy may be due to the fact that oligonucle-
otides 3-5 are 3 nt longerthan oligonucleotide 1 and may form
more stable hybrids with RNA. They also block aberrant
splice sites, allowing the splicing machinery to use the correct
splice sites and, presumably, the correct branch point. In
contrast, in (3110 pre-mRNA, oligonucleotide 1 forces the
splicing machinery to use a suboptimal cryptic branch point
sequence, which may result in relatively inefficient genera-
tion of correctly spliced mRNA.
In the experiments presented above, the oligonucleotides
were added simultaneously with the other components ofthe
splicing reaction. Prehybridization of the oligonucleotides
with the pre-mRNA did not increase their efficiency, and
oligonucleotides added 15 min after the start of the reaction
[i.e., after splicing complexes had a chance to form (26)] were
almost as effective (data not shown). These results indicate
that oligonucleotides containing the 2'-O-methyl modifica-
tion are able to compete effectively for their target sequences
with the splicing factors. The high efficacy of these com-
pounds is most likely due to their strong hybridization with
RNA (21-23). In other experiments they also affected splice
site selection and/or efficiently inhibited pre-mRNA splicing
(27), whereas methylphosphonate oligonucleotides, which
form less stable hybrids, were much less effective (ref. 28;
P. J. Furdon and R.K., unpublished results).
The possibilities of alteration of splicing pathways by
antisense oligonucleotides are not limited to the mutations
tested above. Since it is estimated that up to 15% of all point
mutations in genetic diseases results in defective splicing
(29), the approach described here may have potentially wide
application. Antisense oligonucleotides may be useful in
restoration of correct splicing in other thalassemic mutations
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(10) and in genetic disorders, such as Tay-Sachs syndrome
(30), phenylketonuria (31), and certain forms ofcystic fibrosis
(32), in which mutations leading to aberrant splicing of
pre-mRNA have been identified. They may also promote
reactivation ofcancer suppressor genes that are defective due
to mutations affecting pre-mRNA splicing (33, 34).
It is of interest that oligonucleotide 3 was able to inhibit
aberrant splicing caused by two different mutations. There
are a number of thalassemic mutations that lead to activation
of a single cryptic splice site in exon 1 of the human f-globin
gene (10); therefore, it seems likely that aberrant splicing
could be corrected with a single oligonucleotide complemen-
tary to this site. This property would be very useful if an
antisense approach were applied for therapeutic purposes.
The next logical step in this approach is to demonstrate that
oligonucleotides can efficiently modify splicing pathways in
vivo. A number of studies showed that transmembrane trans-
port of oligonucleotides is possible and can be significantly
improved by various modifications of these compounds,
affecting their chemical properties (1-4). Splice sites have
been shown to provide effective targets for inhibition ofgene
expression by antisense oligonucleotides (35-37). A recent
report indicates that the use of a lipofection procedure
dramatically increases delivery of the oligonucleotides to the
cells and leads to their increased accumulation in the nucleus,
the site of splicing (38). These results suggest that the
approach reported here will also be successful in vivo.
In this work the antisense oligonucleotides were used to
generate correctly spliced mRNA from an aberrant pre-
mRNA substrate in vitro. It is important to note that oligo-
nucleotides 1 and 3 were able to elicit a desired effect by
antisense interaction at sequences distant from the actual
mutations. These results point to the usefulness ofthe in vitro
splicing system for rapid screening of suitable target se-
quences, thus narrowing down the number of oligonucleo-
tides worthy of in vivo testing.
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